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Executive Summary
COVID science is being both done and circulated at a furious pace. While it is inspiring to see 
the research community responding so vigorously to the pandemic crisis, all this activity has 
also created a churning sea of bad data, conflicting results, and exaggerated headlines. With 
representations of science becoming increasingly polarized, twisted and hyped, there is growing 
concern that the relevant science is being represented to the public in a manner that may cause 
confusion, inappropriate expectations, and the erosion of public trust. Here we explore some 
of the key issues associated with the representations of science in the context of the COVID-19 
pandemic. Many of these issues are not new. But the COVID-19 pandemic has placed a spotlight 
on the biomedical research process and amplified the adverse ramifications of poor public 
communication. We need to do better. As such, we conclude with ten recommendations aimed at 
key actors involved in the communication of COVID-19 science, including government, funders, 
universities, publishers, media and the research communities.
Recommendations
We offer broad recommendations that we believe will have relevance beyond this pandemic.
1) The research community—including funding agencies, research institutions, ethics review 
boards, researchers, and publishers—should prioritize and defend the integrity of the 
research process. Federal, provincial and institutional research funding agencies, as well as 
research institutions, should consider how their criteria, incentives and evaluation processes 
might influence how science is framed and communicated to the public. 
2) Researchers should present their work throughout the knowledge creation and translation 
process in a manner that is measured, position their conclusions in the context of the 
broader evidence base, and consider the limitations, strengths and weaknesses of the 
utilized methodologies. Relevant scientific organizations should consider embracing this 
recommendation as an obligation. 
3) Measured and accurate public representations of science are facilitated by transparency 
about the evidence, data and methods. This requires researchers to deposit data and 
results, especially of clinical trials, in appropriate publicly accessible repositories (e.g., 
clinicaltrials.gov).
4) Researchers should monitor how their work (and work relevant to their area of expertise) 
is represented in the public sphere and, when appropriate, correct public misrepresentation 
using a range of mediums, including various social media platforms. Researchers should 
be supported, recognized and incentivized for these kinds of public engagement activities. 
And, when needed, have access to appropriate training.
5) The standard of peer review should remain high regardless of external pressures for 
speed. The research community—such as entities like the CIHR, NSERC, SSHRC, the Council 
of Canadian Academies, etc.—should work closely with academic publishers to develop 
strategies to handle peer review during times of crisis. This should be done in a manner 
that considers ways to improve the sustainability of the peer review process, which currently 
relies on academics to volunteer their time.
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6) Great care should be taken in how research results that haven’t been peer reviewed—such 
as preprints—are represented in the public domain, including emphasizing the preliminary 
nature of conclusions. Further consideration—by research funding entities, universities, 
academic journals, scientific associations, etc.—about the place of preprints and how to 
counter their possible harm on public discourse is required.
7) When issuing press releases or producing publications for the general public, research 
institutions and individual researchers should not exaggerate the benefits or implications 
of research, including clinical trials; should put the work in the context of available and 
accessible evidence, including clinical trial results; and note the limitations of the utilized 
methodologies. As part of the communication process, researchers and research institutions 
should consider creating summaries that are accessible to both the general public and the 
audiences/communities for which the results of the research may be most relevant.
8) Public institutions—such as public health authorities and provincial and federal regulatory 
bodies—should be transparent about the evidence (and other considerations) used to inform 
decisions, including an honest assessment of the current state of knowledge and changing 
nature of science in uncertain times. Public institutions should also avoid dogmatism and be 
free from political interference in the interpretation and representation of science.
9) The news media (and popular press more broadly) should strive to represent science in as 
accurate and informative a manner as possible, including not hyping significance of results 
or the timeframe of translation and not extrapolating the results inappropriately beyond 
the scope of the study. Journalists should also place research in the context of the existing 
body of evidence and recognize, inter alia, the limits of particular methods and the limited 
scientific relevance of anecdotes, testimonials and of a single study.
10) Researchers and science communicators must be mindful of the potential of research to 
be interpreted in a manner that harms individuals, communities, or populations, for example, 
through shaming, stigma or racism. Communications should be undertaken in partnership 
with research participants, with their voices included throughout the research process.
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Let’s Do Better: Public Representations of COVID-19 Science
Introduction
Since the start of 2020, tens of thousands of peer-reviewed academic articles and preprints on 
COVID-19 entered the public domain (Coronavirus Research Publishing 2020). Submission rates 
to prestigious biomedical journals have increased substantially, with some journals receiving triple 
the usual number of submissions (Bauchner, Fontanarosa and Golub 2020).
COVID science is being both done and disseminated at a furious pace. Currently, the median 
time from the submission of an article to acceptance is just six days (Palayew et al. 2020). That is 
an astonishing increase in pace of acceptance from the pre-pandemic speed of around 100 days. 
And some publications made it through peer-review in just one day (Locher et al. 2020).
Wanting science to happen quickly during a pandemic is understandable (Gleick 2020). While it is 
inspiring to see the research community responding so vigorously to the pandemic crisis, all this 
activity has also added to a chaotic information environment by injecting bad data, conflicting 
results, and hyped headlines (Jaklevic 2020). One day a study, published in a renowned biomedical 
journal, is being hailed as definitive data that should (and does) guide our actions and policies 
(Sattui et al. 2020). The next day that same study is retracted (Joseph 2020) (or being asked to be 
retracted) (Mandavilli 2020).
With representations of science becoming increasingly polarized, twisted and hyped, there is 
growing concern that the science is being represented to the pubic in a manner that may cause 
confusion, inappropriate expectations, and the erosion of public trust (Saitz and Schwitzer 2020). 
Here we explore some of the key issues associated with the representations of science in the 
context of the COVID-19 pandemic. This is not meant to be a comprehensive analysis of how 
science is prioritized, done, incentivized, and evaluated (Council of Canadian Academies 2010)—
though we will touch on those topics. Rather, we consider some of the sources and impact of 
problematic representations of COVID-19 science—including the potential to compromise public 
trust and public health initiatives. Many of these issues are not new. But, as we outline below, the 
COVID-19 pandemic has both placed a spotlight on the health research process and amplified the 
adverse ramifications of poor public communication.
The Hydroxychloroquine Story
While there are many examples of less-than-ideal representations of COVID-19 science, the 
hydroxychloroquine controversy stands as a good illustration of both the ways in which things can 
go wrong and the myriad harmful ramifications of those missteps (Sattui et al. 2020).
In mid-March, 2020, French researchers published a preprint suggesting that hydroxychloroquine 
had potential therapeutic benefits in the treatment of COVID-19 (Gautret et al. 2020). The study 
was small (N=80), open-labelled, and almost immediately criticized as being too methodologically 
flawed to justify publication in a peer-reviewed journal (Voss 2020). Indeed, a later academic 
review of the study suggested it was “a non-informative manuscript with gross methodological 
shortcomings” (Rosendaal 2020). As a direct result of this study (which, at the time of this writing, 
has already and unfortunately been cited over 1700 times) and despite these scientific concerns, 
hydroxychloroquine started to receive a great deal of positive media attention and endorsements 
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from prominent individuals like Elon Musk and Donald Trump. This drove up public interest in the 
drug. Indeed, one study found that Internet searches spiked as a result of these endorsements 
(M. Liu et al. 2020) and, more worrisome, so did off-label prescriptions by MDs (Vaduganathan et 
al. 2020).
As the hydroxychloroquine story unfolded—and the hype gained steam (Thompson 2020)—more 
and more researchers around the world started investigating the drug, despite the fact that there 
was (and remains) little evidence to suggest significant (or any) clinical utility (University of Oxford 
- News, 2020; Boulware et al. 2020; Kupferschmidt 2020; Skipper et al. 2020). Then, in mid-June, 
a large study—published in the influential journal The Lancet—concluded that the drug had the 
potential to cause significant adverse events. The study prompted an immediate response from 
the international research community, including causing clinical trials to be temporarily stopped 
due to safety concerns. Noting anomalies in the dataset used to support the conclusions of harm, 
many other scientists almost immediately criticized the study, and it was quickly retracted (Mahase 
2020b). 
The hydroxychloroquine story continues to evolve (Gonsalves 2020). More evidence—including 
both observational and clinical trials of varying methodological strengths—has been produced 
and suggests the drug is unlikely to be beneficial in the context of COVID-19 (Qaseem et al. 2020). 
Indeed, because of the lack of compelling evidence, key clinical trials have been discontinued, 
including trials sponsored by the NIH (Kiley 2020) and the WHO (WHO 2020). In addition, concerns 
about significant side effects remain (Downes et al. 2020; U.S. Food & Drug Admin 2020).
There are, of course, other examples of both poor science and poor science communication in the 
context of COVID-19 related research (Day 2020; Schwitzer 2020). But the hydroxychloroquine 
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controversy—which took flight due to public representations and celebrity endorsements 
of questionable preliminary research—highlights the breadth of adverse outcomes that can 
emerge when science is communicated poorly, including injecting inefficiencies into COVID-19 
research efforts (e.g., making it more difficult to recruit participants into well-designed clinical 
trials) (Ledford 2020), spurring questionable public investment in further research (Herper and 
Riglin 2020), causing poor pharmaceutical allocation decisions (Mahase 2020a), and resource 
shortages (hydroxycholorquine shortages—potentially affecting people with chronic immunologic 
conditions—were reported in most Canadian provinces) (Mendel et al. 2020), encouraging 
unnecessary and potentially harmful prescriptions (Lovelace Jr. 2020), and creating unjustified 
and heightened public expectations (e.g., 23% of Canadians—and 30% of Quebecers—wrongly 
believe the drug is effective) (Everts and Greenberg 2020). The initial hype and subsequent 
retracted research results have fed conspiracy theories (Mikkelson 2020), been used to polarize 
public discourse, and, perhaps most problematic, may have contributed to a decrease in public 
trust of science (Laurent 2020).
Despite the mounting evidence that it does not work, a belief in hydroxychloroquine endures for 
some—in part because it has become associated with a particular ideological position due to the 
connection with prominent politicians like Trump (Dearment 2020). Once a belief becomes part 
of an individual’s personal identity, it can be very difficult to change their mind (Kaplan, Gimbel 
and Harris 2016). 
Public Perceptions
Building and maintaining public trust—including in science and scientific institutions—is particularly 
critical during a pandemic (Balog-Way and McComas 2020; Udow-Phillips and Lantz 2020). For 
example, there is some evidence (albeit observational in nature) which correlates trust in relevant 
institutions with the likelihood of engaging in the needed preventative behaviours (Devine et al. 
2020; Fukuyama 2020; Goldberg et al. 2020; Lep, Babnik and Hacin Beyazoglu 2020). An analysis 
from France, for instance, found that “high-trust regions decrease their mobility related to non-
necessary activities significantly more than low-trust regions” (Bargain and Aminjonov 2020). This 
study is consistent with research from Australia that correlated trust in government and health 
authorities with greater adoption of physical distancing and hygiene-related behaviours (Seale 
et al. 2020). And research from Johns Hopkins University that looked specifically at distrust of 
science found that it was strongly correlated with a failure to adopt preventative strategies—like 
physical distancing—and, unsurprisingly, listening to public health experts’ advice on COVID-19 
(Barry, Han and McGinty 2020). A lack of trust in relevant institutions has also been found to be 
associated with an increased belief in COVID-19 myths and conspiracy theories (Pickles et al. 
2020).
The Canadian public is following the developments surrounding the pandemic very closely. A 
June 2020 survey by Carleton University, for example, found that 82% of Canadians are monitoring 
COVID-19 news “every day” (53%) or “most days” (29%) (Greenberg and Everts 2020). As a 
result, the public are observing the messy but usually concealed process of building scientific 
understanding (which can include missteps) and the shifting nature of scientific consensus. And 
they are seeing the dramatic headlines, the retractions, and the disagreements among scientific 
experts. As a result, there is concern that the many less-than-ideal representations of science 
will erode public trust (Drage O’Reilly 2020), especially as the pandemic drags on and global 
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sentiment shifts, as some research indicates, from fear towards frustration and anger (Lwin et al. 
2020).
A recent study from the London School of Economics suggests that the COVID-19 crisis may have 
a negative impact on people’s perceptions of scientists, especially among those in the public with 
little or no scientific education (Aksoy, Eichengreen and Saka 2020a). Specifically, the researchers 
conclude—using past pandemics as a guide—that the COVID-19 crisis “will reduce confidence 
in individual scientists, worsen perceptions of their honesty, and weaken the belief that their 
activities benefit the public” (Aksoy, Eichengreen and Saka 2020a). Another study, a survey from 
France, found a 10% drop in trust in science—driven mostly by frustration surrounding the two 
polarizing topics: the hydroxychloroquine debacle and policy reversals surrounding the use of 
masks (Matthew 2020).
To date, the public discourse in Canada around COVID-19 has not been as polarized as we have 
seen in the United States and in some other countries (Merkley et al. 2020; Padilla and Hípola 
2020). Trust in our health and science institutions remains relatively high (Statistics Canada 2020). 
If asked, most Canadians will still say they have confidence in academics, healthcare providers, 
and public health officials (Statistics Canada 2020). Still, we should not be complacent (Robinson 
2020). There is some evidence—pre-pandemic—that trust in science is falling and that many 
Canadians view the scientific community as elitist (Ontario Science Centre 2017; Semeniuk 2018; 
Weber 2019). Other research has suggested the pandemic could result in a general and long-term 
erosion of trust in public institutions (Aksoy, Eichengreen and Saka 2020b). And there are complex 
trust issues to be considered in the context of particular populations—particularly those, such 
as Indigenous peoples (Kolopenuk 2020; Government of Canada 2019), that have been poorly 
served or even harmed by existing research institutions. 
Trust can be lost quickly—and with dire consequences (Robinson 2020). Indeed, the public 
perception of science and issues of trust are likely to become even more salient in the context 
of vaccine uptake. Studies have found that a lack of trust in science is associated with decreased 
intention to get a COVID-19 vaccine (Palamenghi et al. 2020). Many in Canada already have 
concerns about any vaccine and hesitancy is on the rise. An August 2020 survey found that only 
46% of Canadians agree that they “would get a vaccination as soon as one become available to 
me” and three-in-five worry about safety (Angus Reid Institute 2020). Rhetoric from the anti-vaccine 
community is clearly having an adverse impact on public perceptions, in part because it leverages 
(and stokes) concerns about the adequacy of relevant science (Crow and Stacey 2020). Given fear 
about the potential for political interference with the vaccine research process—particularly in 
the US (LaFraniere et al. 2020)—the social and health issues associated with the erosion of trust 
in scientific institutions and science-informed policy decisions seem likely to intensify. Indeed, an 
August 2020 survey found that “78% of Americans worry the Covid-19 vaccine approval process 
is being driven more by politics than science” (Silverman 2020).
Communication and the Scientific Community 
Obviously, an essential component in the creation of accurate, balanced and trustworthy 
representations of science is to ensure that the science is done well and in a manner that is 
transparent, which includes ensuring public access to the relevant data (e.g., disposition publicly 
accessible repositories). There is growing concern that the pressures associated with production 
and dissemination of COVID-19 science is leading to poor quality science (Dinis-Oliveira 2020). 
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One of the fastest ways to create confusion and lose public trust is to publish and publicize weak, 
careless or, worse, fraudulent research (Yarborough 2014). Unfortunately, this may be happening 
too often in this era of panicky, pandemic publishing (Blaming 2020; Steinberg 2020)—which, as 
one commentator suggests, has created “a deluge of poor quality research” that is “sabotaging 
an effective evidence based response” (Glasziou, Sanders and Hoffmann 2020). This includes 
high profile and frequent retractions of peer-reviewed journal articles (Yeo-Teh and Tang 2020), 
though it is still unclear how unusual—if at all—the retraction rate is (Abritis, Marcus and Oransky 
2020). (As of this writing, Retraction Watch, an entity that monitors this kind of activity, reports 36 
retracted COVID-19 studies.)
While a detailed analysis of existing research institutions and incentive structures is beyond the 
scope of this paper, it seems axiomatic that maintaining integrity of the research process should 
be a priority. During a pandemic there is an understandable sense of urgency (Tingley 2020). But 
the desire for quick results should not be allowed to erode scientific standards (Pang and Elkhodiry 
2020). As succinctly put by Alex John London and Jonathan Kimmelman, “Crises are no excuse 
for lowering scientific standards” (London and Kimmelman 2020). And this point was echoed by 
H. Clifford Lane and Anthony Fauci, “scientifically robust and ethically sound clinical research 
remains the quickest and most efficient pathway to effective treatment and prevention strategies 
for patients with Covid-19” (Lane and Fauci 2020). Unfortunately, there is some evidence that 
much of research that is currently being done—as measured by an analysis of registered clinical 
trials—is expected to produce only a “low level of evidence” as there are few high quality RCTs 
and, as a result, “most studies likely will not yield meaningful scientific evidence” (Di Girolamo 
and Meursinge Reynders 2020; Pundi et al. 2020). 
The push for speed can also create problems for how the relevant science is published and 
represented to the public and decision makers. There is, for example, concern that the huge 
volume of paper submissions is straining the peer-review process—as highlighted by the paper 
that started the hydroxychloroquine controversy (Locher et al. 2020)—and that “weak, or even 
wrong, findings disseminate, amplify, and potentially enter into scientific and popular discourse” 
(Bell and Green 2020). While some of this work has been quickly retracted (Retracted coronavirus 
(COVID-19) papers), once the work has been circulated by the popular press and on social media, 
it can be hard to undo the damage—including adversely impacting public trust (Wysong 2020). 
As a result of these concerns, there have been recommendations about how to improve the 
publication and peer-review process (Bauchner, Fontanarosa and Golub 2020), such as establishing 
new editorial standards to maintain quality during public health emergencies and requiring peer 
reviewers to be adequately trained (Bazdaric and Smart 2020; Palayew et al. 2020). Some journals—
including The Lancet, the publication involved in one of the recent high-profile COVID-19 related 
retractions (Medical Xpress 2020; Rabin 2020)—have already suggested that the peer-review 
process will need to be adjusted to ensure greater scrutiny of the relevant methods and data 
(Caulfield 2020). 
Addressing the explosion of preprints—that is, the distribution of research prior to peer-review—
is also critical (Van Schalkwyk et al. 2020). Preprints can be a valuable tool for the dissemination of 
data and for generating constructive critiques from colleagues. (Most journals, including 80% of 
the highest impact journals, allow preprint dissemination prior to submission (Massey et al. 2020)). 
But preprints can also result in the circulation of unverified and poor research in a manner that can 
confuse public discourse (the hydroxychloroquine issue started with a preprint). Preprints are being 
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produced and accessed at an incredibly high pace during the pandemic. And they are having 
an impact on public and policy discourse (Majumder and Mandl 2020). One study (a preprint 
about preprints, ironically) found that the pandemic has resulted in an increased academic, public 
and news media engagement with preprints. For example, they found “COVID-19 preprints are 
accessed and distributed at least 15 times more than non-COVID-19 preprints” (Fraser et al. 
2020). As a result, some scholars are striving to develop an informal and publicly accessible, rapid 
review of preprints that will help to inform both the public and policymakers (Eisen and Tibshirani 
2020).
How scientists communicate their work to the media—on social media, and directly to the 
public—also requires consideration. How work is shared on social media, for example, can shape 
both subsequent citations to the work but also public and policy discourse (Kousha and Thelwall 
2020). There are growing pressures on the scientific community to present their work in overly 
enthusiastic terms. Indeed, there are forces and incentives throughout the knowledge creation 
process that can encourage hyped representations of science (Bubela 2006; Bubela et al. 2009; 
Caulfield and Condit 2012), from the submission of grants (Matthews 2016), to the write up of 
results (Vinkers, Tijdink and Otte 2015), to the crafting of institutional press releases (Yavchitz et al. 
2012), to the interactions with the popular press (Kamenova and Caulfield 2015). And as we have 
seen in other domains, this hype (Ball 2015) can have a profound impact on public understanding, 
science and health policy (Caulfield 2018), the marketing of associated products and therapies 
(Caulfield et al. 2016), and, perhaps (Master and Resnik 2013), public trust (Resnick 2019). 
It is essential for the scientific community to remain part of the public conversation, including 
challenging misrepresentations and spin used to further polarize public perceptions. But it is 
also essential for those in research community to portray their work in a measured and accurate 
manner (Leeming 2018), including reflecting on limitations of the work and how it fits in the 
broader body of evidence. 
It is equally important for a wide range of communities to be meaningfully engaged in the scientific 
conversation, especially for research that informs public health interventions (Tworek, Beacock 
and Ojo 2020). These interventions have both intended and unintended consequences, and the 
economic, social, and health burdens are unequally distributed. In the context of COVID-19 there 
is evidence that some communities are experiencing disproportionate disease burden and, at the 
same time, have increased levels of distrust toward, for example, the vaccine research process 
(Hoffman, 2020). Research best practices in health and social science domains have increasingly 
integrated the voices of community partners and patients, from the inception of research 
questions, methodological design, research conduct and the interpretation and dissemination or 
communication of results. This last point is imperative when scientific findings may be interpreted 
in a manner that leads to increased stigma or overt racism against individuals, communities, or 
populations. This philosophy of public engagement is enshrined in Canada’s Tri-Council Policy 
Statement: Ethical Conduct for Research Involving Humans (Tri-Council Policy Statement, 2018) 
and the national Strategy for Patient-Oriented Research (Strategy, 2019). The recognized need for 
engagement is based on the premise that public trust may be enhanced if those most impacted 
by the research are active partners. While beyond the scope of this paper, Indigenous health 
research goes one step further to be increasingly led and controlled by Indigenous communities 
(The First Nations Principles of OCAP).
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Public Health Policy and Science Communication
Public health authorities—regional, national and international—are a vital source of scientific 
information during a pandemic. While controversy has surrounded some of the recommendations 
that have flowed from entities like the World Health Organization, the U.S. Centers for Disease 
Control and Prevention (CDC) and the Public Health Agency of Canada (PHAC), clinicians, 
healthcare institutions, educators, the public and politicians turn to public health authorities for 
both updates on emerging evidence and recommendations on how best to proceed (Carleton 
2020; Goldberg et al. 2020). As such, it is critically important that communication of science is 
done in a manner that maintains public trust in both the science and the relevant institutions.
Public health authorities should, for example, be honest and clear about the state of the science 
used to inform recommendations (Leask 2020; Mello, Greene and Sharfstein 2020; Robinson 
2020). This includes “being transparent and open about what is known and unknown about SARS-
CoV-2 virus and COVID-19 disease” (Pak and Adegboye 2020). Unsupportable or oversimplified 
dogmatic pronouncements of benefit or harm—no matter how noble the justification—only 
help to feed a polarization process that, long-term, seems likely to do real damage to public 
trust and the perception of science and scientists. Attention must also be paid to the mode 
of communication—visual media are distinct from print sources, necessitating spokespeople, 
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settings, and congruence in messaging for clarity and maintenance of public confidence (Luth, 
Jardine and Bubela 2013).
As mentioned above, the evolving recommendations about the use of masks (Zhang et al. 2020) 
in public has been pointed to as a possible engine of public distrust (Urback 2020). Commentators 
have claimed that this evolution in guidelines—or the “flip flop”, as those critical of the mask policies 
have labelled it (Toronto Sun 2020)—has facilitated a reduction in trust in public health authorities 
(Gerson 2020). In such situations, public health authorities should not shy away from being frank 
about the equivocal and changing nature of the evidence. As noted by public health experts, 
Rutter, Wolert and Greenhalph, during a pandemic “most data will be flawed or incomplete” and 
we need to “be honest and transparent about this” (Rutter, Wolpert and Greenhalgh 2020). Of 
course, this is how science almost always unfolds. This situation is not unique to the pandemic. 
As such, ensuring that the public understands the nature of scientific research and knowledge 
translation process is also critically important. 
During a pandemic, public health decisions often need to be made using a less-than ideal body 
of evidence (Greenhalgh 2020). And recommendations that are based on emerging science will 
(and should) evolve. Revising a position as new evidence and/or social conditions change should 
not be viewed as a failure of the system (Dupré 2020). While it is understandable that public health 
officials may be tempted to provide strong and unequivocal messaging, it is important to be explicit 
about the ambiguities of the evidence. Indeed, there is some evidence that being transparent 
about uncertainties can actually heighten credibility (Ratcliff et al. 2018), trust (Fleerackers 2020) 
and public understanding (Jensen et al. 2011; Porter 2020). Public health authorities can provide 
a clear and actionable message that mobilizes our shared values in a manner that still accurately 
reflects the available science. Indeed, as noted by science communication expert Dominique 
Brossard, “at the end of the day, it’s better to say ‘the best practice is this, although we’re not 
100% sure and we’ll let you know as soon as we know more’” (Drage O’Reilly 2020). 
Some have suggested that it is important to prime the public with supportable rationales as to why 
additional preventative strategies may be required, including details about evidence and goals 
(Seale et al. 2020). And public health entities also need to use a wide range of communication 
platforms, especially social media, to ensure that science-informed messages play a dominant 
role in public discourse (Lovari 2020). This may include working with social media platforms to 
facilitate the “upranking” of “links to recommendations from recognised health authorities” 
(Limaye et al. 2020).
Perhaps most worrisome is the issue of political influence. Decisions by science-based health 
institutions must be done in an independent manner and devoid of politically motivated interference. 
To do otherwise can greatly compromise the ability for these institutions to have an impact on 
public health. Recent action by the United State’s FDA (e.g., the messaging and questionable 
approval of convalescent plasma treatment) (Kupferschmidt and Cohen 2020; McGinley et al. 
2020) and the CDC (e.g., the policy change on the testing of asymptomatic individuals) (Sheridan 
2020; Troisi 2020) has highlighted how political interference can impact both public trust and the 
public representations of science (Wilson 2020). 
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Media Coverage
How the media cover science, particularly during a pandemic (Gozzi et al. 2020; Q. Liu et al. 
2020), is also important. It can have an impact on public perceptions and attitudes (Zheng, Goh 
and Wen 2020), policy development, clinical practice, and research priorities. And news coverage 
can facilitate the spread of misinformation and the polarization of public discourse (Green et al. 
2020). 
Those working in the popular press—whether for TV, radio, print media, or online sources—should 
take care not to hype or misrepresent science, including the certainty of a result (Abbas and Lamb 
2020; Strazewski 2020). True game-changing breakthroughs are vanishingly rare (for example, 
fewer than 10% of experimental drugs that are promising enough to be in a clinical trial will be 
approved for clinical use) (Lowe 2019). The reality is that scientific research is an iterative and, 
in general, slow process. The media, however, prefer definitive pronouncements of near future 
benefit.
There have been numerous journalist organizations that have emphasized the importance of 
accurate and measured reporting (Coronavirus: Resources for Reporters 2020; Journalists’ 
Resources 2020; Hanage and Lipsitch 2020; Mulcahey 2020). Still, much of the reporting has 
been less than ideal and, as highlighted by the hydroxychloroquine situation, with significant 
ramifications. As noted in an analysis by science communication experts Saitz and Schwitzer, the 
news media too often focus on (and hype) a single study and/or overemphasizes the potential 
meaning of the results without putting the research in the context of the existing available evidence 
(Saitz and Schwitzer 2020).
Some have also argued that the content of what the media have covered, especially in the early 
days of the pandemic, was problematic. One study, for example, found that news TV coverage 
mostly emphasized death and death rates and said little about the science surrounding preventative 
behaviours (Basch et al. 2020).
While the news media can certainly improve their practices, it shouldn’t be forgotten that much 
of the misinformation and hype that appears in the press comes from researchers and research 
institutions (Caulfield and Condit 2012; Woolston 2014). There is a relationship between how 
research is represented in, for example, press releases—which often hype research results—and 
how the science is represented to the public. And, of course, much of the misinformation about 
the COVID-19 science is happening on social media. It is being created and circulated not by 
professional journalists but by the users of social media platforms. Indeed, social media has been 
identified as a primary driver of COVID-19 misinformation (and those who get their news from 
social media are more likely to believe misinformation) (Caulfield 2020; Bridgman et al. 2020). 
Still, the popular press remains an important source of pandemic information and can have a 
significant impact on how the science is perceived and utilized.
Discussion and Recommendations
Science has always been under various external pressures, including ideological mandates (Baran, 
Goldman and Zelikova 2019), military and national defence demands (Finkbeiner 2018), and 
the ever-present profit motive. And, of course, the incentive structures built into academia—
rewarding publication quantity and “impact factors” over quality and social benefit (Plackett 
2020)—also shape, for better or worse, the research enterprise. The policy decisions that are 
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made by governments, funding agencies and research institutions about how to support and 
fund research—including the commercialization push that has been embraced by almost every 
Canadian research funding entity (Caulfield and Ogbogu 2015)—help to influence how that 
research is done and represented to the public. 
We recognize that a deep reflection on these complex, interrelated and systemic influences 
on public representations of research is likely warranted. We also recognize that improving 
representations of science will not, on its own, necessarily lead to better policies and a more 
informed public. These are big and complex challenges. Our goal here, however, is narrower and 
is focused on several of the key actors involved in the communication of COVID-19 science. How 
science has been communicated during this pandemic has had an impact on public perceptions, 
health and science policy, and the uptake of preventative strategies. But the communication 
problems that have unfolded during this public health crisis are not new. Indeed, in many ways 
they have served to highlight the adverse impact of many long-standing concerns about how 
science is being communicated, including, inter alia, issues associated with interpretation of 
research results, the publication process, press releases, and media coverage. As such, we offer 
broad recommendations that we believe will have relevance beyond this pandemic. 
1) The research community—including funding agencies, research institutions, ethics review 
boards, researchers, and publishers—should prioritize and defend the integrity of the 
research process. Federal, provincial and institutional research funding agencies, as well as 
research institutions, should consider how their criteria, incentives and evaluation processes 
might influence how science is framed and communicated to the public. 
2) Researchers should present their work throughout the knowledge creation and translation 
process in a manner that is measured, position their conclusions in the context of the 
broader evidence base, and consider the limitations, strengths and weaknesses of the 
utilized methodologies. Relevant scientific organizations should consider embracing this 
recommendation as an obligation. 
3) Measured and accurate public representations of science are facilitated by transparency 
about the evidence, data and methods. This requires researchers to deposit data and 
results, especially of clinical trials, in appropriate publicly accessible repositories (e.g., 
clinicaltrials.gov).
4) Researchers should monitor how their work (and work relevant to their area of expertise) 
is represented in the public sphere and, when appropriate, correct public misrepresentation 
using a range of mediums, including various social media platforms. Researchers should 
be supported, recognized and incentivized for these kinds of public engagement activities. 
And, when needed, have access to appropriate training.
5) The standard of peer review should remain high regardless of external pressures for 
speed. The research community—such as entities like the CIHR, NSERC, SSHRC, the Council 
of Canadian Academies, etc.—should work closely with academic publishers to develop 
strategies to handle peer review during times of crisis. This should be done in a manner 
that considers ways to improve the sustainability of the peer review process, which currently 
relies on academics to volunteer their time.
6) Great care should be taken in how research results that haven’t been peer reviewed—such 
as preprints—are represented in the public domain, including emphasizing the preliminary 
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nature of conclusions. Further consideration—by research funding entities, universities, 
academic journals, scientific associations, etc.—about the place of preprints and how to 
counter their possible harm on public discourse is required.
7) When issuing press releases or producing publications for the general public, research 
institutions and individual researchers should not exaggerate the benefits or implications 
of research, including clinical trials; should put the work in the context of available and 
accessible evidence, including clinical trial results; and note the limitations of the utilized 
methodologies. As part of the communication process, researchers and research institutions 
should consider creating summaries that are accessible to both the general public and the 
audiences/communities for which the results of the research may be most relevant.
8) Public institutions—such as public health authorities and provincial and federal regulatory 
bodies—should be transparent about the evidence (and other considerations) used to inform 
decisions, including an honest assessment of the current state of knowledge and changing 
nature of science in uncertain times. Public institutions should also avoid dogmatism and be 
free from political interference in the interpretation and representation of science.
9) The news media (and popular press more broadly) should strive to represent science in as 
accurate and informative a manner as possible, including not hyping significance of results 
or the timeframe of translation and not extrapolating the results inappropriately beyond 
the scope of the study. Journalists should also place research in the context of the existing 
body of evidence and recognize, inter alia, the limits of particular methods and the limited 
scientific relevance of anecdotes, testimonials and of a single study.
10) Researchers and science communicators must be mindful of the potential of research to 
be interpreted in a manner that harms individuals, communities, or populations, for example, 
through shaming, stigma or racism. Communications should be undertaken in partnership 
with research participants, with their voices included throughout the research process.
Figure 1. Mapping the actions to improve 
representations of science
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